Enzalutamide

Anti-KAZALD1 Kazal-type serine peptidase inhibitor domain 1,

Anti-KAZALD1 Kazal-type serine peptidase inhibitor domain 1,

Anti-OTUD7B OTU deubiquitinase 7B, 25ul UN 1687 6.1 PG2

A small molecule enolase inhibitor.

A small molecule enolase inhibitor.

A small molecule enolase inhibitor.

Deutenzalutamide (Enzalutamide-d 3 ) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.In VitroStable heavy isotopes of hydrogen, carbon, and

Deutenzalutamide (Enzalutamide-d 3 ) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.In VitroStable heavy isotopes of hydrogen, carbon, and

Deutenzalutamide (Enzalutamide-d 3 ) is a developed deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.In VitroStable heavy isotopes of hydrogen, carbon, and

Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib.Form:SolidIC50&amp: Target:PI3K.

Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib.Form:SolidIC50&amp: Target:PI3K.

Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib.Form:SolidIC50&amp: Target:PI3K.